Fosaprepitant
- Generic Name
- Fosaprepitant
- Brand Names
- Emend, Focinvez, Ivemend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22F7N4O6P
- CAS Number
- 172673-20-0
- Unique Ingredient Identifier
- 6L8OF9XRDC
- Background
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
- Indication
Fosaprepitant is indicated in adult and pediatric patients ≥6 months of age, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin. It is also indicated for the treatment of delayed nausea and vomiting with initial and repeat courses of moderately emetogenic cancer chemotherapy.
- Associated Conditions
- Acute Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by highly emetogenic chemotherapy, Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) caused by moderately emetogenic chemotherapy
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificBreakthrough Nausea and Vomiting
- Interventions
- Drug: systemic chemotherapyOther: survey administrationProcedure: quality-of-life assessment
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT01031953
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT00945321
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
- Conditions
- Stage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the NasopharynxNausea and VomitingStage III Squamous Cell Carcinoma of the LarynxStage III Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage III Squamous Cell Carcinoma of the HypopharynxStage III Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the Larynx
- Interventions
- Other: Functional Living Index-Emesis QuestionnaireBehavioral: Emesis DiaryRadiation: Radiotherapy
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 6
- Registration Number
- NCT00895245
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 92
- Registration Number
- NCT00818259
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2322
- Registration Number
- NCT00619359
Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 362
- Registration Number
- NCT00571168
- Locations
- 🇩🇪
University Hospital of Heidelberg, Department V, Heidelberg, Germany
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Drug: Comparator; Placebo (unspecified)
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 848
- Registration Number
- NCT00337727
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.